Teladoc (NYSE:TDOC)‘s stock had its “overweight” rating reiterated by stock analysts at KeyCorp in a report issued on Thursday, March 15th. They currently have a $50.00 target price on the health services provider’s stock, up from their prior target price of $41.00. KeyCorp’s price target points to a potential upside of 27.71% from the company’s current price.
A number of other equities research analysts also recently issued reports on TDOC. BidaskClub downgraded Teladoc from a “hold” rating to a “sell” rating in a research report on Wednesday, November 15th. Canaccord Genuity set a $42.00 price target on Teladoc and gave the company a “buy” rating in a research report on Friday, November 17th. Cantor Fitzgerald reissued a “hold” rating and set a $31.00 price target on shares of Teladoc in a research report on Monday, November 20th. Oppenheimer boosted their price target on Teladoc from $40.00 to $45.00 and gave the company an “outperform” rating in a research report on Tuesday, November 21st. Finally, CIBC reissued an “outperform” rating and set a $45.00 price target (up previously from $40.00) on shares of Teladoc in a research report on Tuesday, November 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $41.67.
Teladoc stock traded down $2.25 during trading on Thursday, hitting $39.15. The company’s stock had a trading volume of 748,350 shares, compared to its average volume of 826,499. The firm has a market capitalization of $2,555.48, a P/E ratio of -23.73 and a beta of 0.36. Teladoc has a 1-year low of $22.73 and a 1-year high of $44.65. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.37.
Teladoc (NYSE:TDOC) last released its earnings results on Tuesday, February 27th. The health services provider reported ($0.50) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.10). Teladoc had a negative net margin of 45.77% and a negative return on equity of 20.95%. The business had revenue of $77.14 million during the quarter, compared to analyst estimates of $76.14 million. equities analysts predict that Teladoc will post -1.37 EPS for the current year.
In related news, SVP Andrew Turitz sold 19,245 shares of the business’s stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $39.25, for a total value of $755,366.25. Following the transaction, the senior vice president now owns 16,700 shares in the company, valued at $655,475. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Mark Hirschhorn sold 100,000 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $39.60, for a total value of $3,960,000.00. Following the completion of the transaction, the chief financial officer now owns 98,960 shares in the company, valued at approximately $3,918,816. The disclosure for this sale can be found here. Insiders sold 364,494 shares of company stock valued at $14,665,947 in the last ninety days. Company insiders own 4.47% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the stock. American International Group Inc. lifted its stake in shares of Teladoc by 8.1% in the third quarter. American International Group Inc. now owns 36,079 shares of the health services provider’s stock worth $1,196,000 after acquiring an additional 2,697 shares in the last quarter. Emerald Advisers Inc. PA lifted its stake in shares of Teladoc by 0.5% in the fourth quarter. Emerald Advisers Inc. PA now owns 566,096 shares of the health services provider’s stock worth $19,728,000 after acquiring an additional 2,784 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Teladoc in the fourth quarter worth about $101,000. Brown Advisory Inc. lifted its stake in shares of Teladoc by 38.3% in the third quarter. Brown Advisory Inc. now owns 10,521 shares of the health services provider’s stock worth $348,000 after acquiring an additional 2,915 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its stake in shares of Teladoc by 7.6% in the third quarter. Russell Investments Group Ltd. now owns 48,941 shares of the health services provider’s stock worth $1,622,000 after acquiring an additional 3,442 shares in the last quarter.
WARNING: This report was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/08/teladoc-tdoc-receives-overweight-rating-from-keycorp.html.
Teladoc Company Profile
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.